NMDP focuses on smooth transition to licensing of Class-A and B medical devices

The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr

The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.

Health Minister Mandaviya addresses inaugural ceremony of training programme for senior administrative medical officers of CGHS

Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing

Import of Medical Devices Up by Record 41% in FY22: AiMeD

India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21

Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP

The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements

Govt introduces 'Draft of New Drugs, Medical Devices and Cosmetics Bill, 2022'

The Bill aims to amend and consolidate the law relating to the import, manufacture, distribution and sale of drugs, medical devices and cosmetics

Themis Medicare’s VIRALEX effective against viral respiratory infections

Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.